Dynavax Technologies (DVAX) Scheduled to Post Earnings on Wednesday

Dynavax Technologies (NASDAQ:DVAX) will be posting its quarterly earnings results after the market closes on Wednesday, May 8th. Analysts expect Dynavax Technologies to post earnings of ($0.04) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Dynavax Technologies Stock Down 0.9 %

Shares of NASDAQ DVAX opened at $11.64 on Tuesday. The business has a fifty day simple moving average of $12.11 and a 200 day simple moving average of $13.05. The company has a debt-to-equity ratio of 0.41, a quick ratio of 12.96 and a current ratio of 13.81. Dynavax Technologies has a one year low of $10.57 and a one year high of $15.15.

Analyst Ratings Changes

DVAX has been the subject of a number of recent research reports. William Blair restated an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 23rd. StockNews.com cut Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Friday, April 26th. Finally, The Goldman Sachs Group initiated coverage on Dynavax Technologies in a research report on Thursday, February 1st. They issued a “neutral” rating and a $20.00 price target on the stock. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Dynavax Technologies presently has a consensus rating of “Moderate Buy” and an average target price of $25.00.

Insider Buying and Selling at Dynavax Technologies

In other news, CAO Justin Burgess sold 20,526 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $12.78, for a total transaction of $262,322.28. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 2.98% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.